How do clinical trial participants compare to other patients with schizophrenia?

Schizophrenia Research

Volumn 130, Issue 1-3, 2011, Pages 34-39

  Barnett, Paul G ^a,b   Scott, Jennifer Y ^a   Rosenheck, Robert A ^c,d  

^a VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adherence; Anti psychotic medication; Cost; Schizophrenia

Indexed keywords

NEUROLEPTIC AGENT; RISPERIDONE;

ADULT; AFRICAN AMERICAN; ARTICLE; CONTROLLED STUDY; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; PATIENT ATTITUDE; PATIENT COMPLIANCE; PATIENT PARTICIPATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SUBSTANCE ABUSE; VETERANS HEALTH;

ADULT; ANTIPSYCHOTIC AGENTS; CLINICAL TRIALS AS TOPIC; COHORT STUDIES; COSTS AND COST ANALYSIS; FEMALE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATIENT COMPLIANCE; RISPERIDONE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; UNITED STATES; UNITED STATES DEPARTMENT OF VETERANS AFFAIRS;

EID: 79960332442     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2011.03.033     Document Type: Article

References (27)

1. Bai Y.M., Ting Chen T., Chen J.Y., Chang W.H., Wu B., Hung C.H., Kuo Lin W. Equivalent switching dose from oral risperidone to risperidone long-acting injection: a 48-week randomized, prospective, single-blind pharmacokinetic study. J. Clin. Psychiatry 2007, 68:1218-1225.
2. Box G.E.P., Cox D.R. An analysis of transformations. J. Royal Stat. Soc. Series B (Method.) 1964, 26:211-252.
3. Cameron A.C., Trivedi P.K. Regression Analysis of Count Data 1998, Cambridge University Press.
4. Chue P., Eerdekens M., Augustyns I., Lachaux B., Molcan P., Eriksson L., Pretorius H., David A.S. Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets. Eur. Neuropsychopharmacol. 2005, 15:111-117.
5. Chue P.S., Heeg B., Buskens E., van Hout B.A. Modelling the impact of compliance on the costs and effects of long-acting risperidone in Canada. Pharmacoeconomics 2005, 23(Suppl 1):62-74.
6. Duggan M. Do new prescription drugs pay for themselves? The case of second-generation antipsychotics. J. Health Econ. 2005, 24:1-31.
7. Eaddy M., Grogg A., Locklear J. Assessment of compliance with antipsychotic treatment and resource utilization in a medicaid population. Clin. Ther. 2005, 27:263-272.
8. Edwards N.C., Locklear J.C., Rupnow M.F., Diamond R.J. Cost effectiveness of long-acting risperidone injection versus alternative antipsychotic agents in patients with schizophrenia in the USA. Pharmacoeconomics 2005, 23(Suppl 1):75-89.
9. Fleischhacker W.W., Eerdekens M., Karcher K., Remington G., Llorca P.M., Chrzanowski W., Martin S., Gefvert O. Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic. J. Clin. Psychiatry 2003, 64:1250-1257.
10. Gilbody S., Wahlbeck K., Adams C. Randomized controlled trials in schizophrenia: a critical perspective on the literature. Acta Psychiatr. Scand. 2002, 105:243-251.
11. Gilmer T.P., Dolder C.R., Lacro J.P., Folsom D.P., Lindamer L., Garcia P., Jeste D.V. Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. Am. J. Psychiatry 2004, 161:692-699.
12. Hofer A., Hummer M., Huber R., Kurz M., Walch T., Fleischhacker W.W. Selection bias in clinical trials with antipsychotics. J. Clin. Psychopharmacol. 2000, 20:699-702.
13. Johnsen E., Jorgensen H.A. Effectiveness of second generation antipsychotics: a systematic review of randomized trials. BMC Psychiatry 2008, 8:31.
14. Kane J.M., Eerdekens M., Lindenmayer J.P., Keith S.J., Lesem M., Karcher K. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am. J. Psychiatry 2003, 160:1125-1132.
15. Keks N.A., Ingham M., Khan A., Karcher K. Long-acting injectable risperidone v. olanzapine tablets for schizophrenia or schizoaffective disorder. Randomised, controlled, open-label study. Br. J. Psychiatry 2007, 191:131-139.
16. Lindenmayer J.P., Eerdekens E., Berry S.A., Eerdekens M. Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics. J. Clin. Psychiatry 2004, 65:1084-1089.
17. Manning W.G., Mullahy J. Estimating log models: to transform or not to transform?. J. Health Econ. 2001, 20:461-494.
18. Moller H.J., Llorca P.M., Sacchetti E., Martin S.D., Medori R., Parellada E. Efficacy and safety of direct transition to risperidone long-acting injectable in patients treated with various antipsychotic therapies. Int. Clin. Psychopharmacol. 2005, 20:121-130.
19. Petersen L.A., Byrne M.M., Daw C.N., Hasche J., Reis B., Pietz K. Relationship between clinical conditions and use of Veterans Affairs health care among Medicare-enrolled veterans. Health Serv. Res. 2010, 45:762-791.
20. Render M.L., Nowak J., Hammond E.K., Roselle G. Methods for estimating and comparing VA outpatient drug benefits with the private sector. Med. Care 2003, 41:II61-II69.
21. Thieda P., Beard S., Richter A., Kane J. An economic review of compliance with medication therapy in the treatment of schizophrenia. Psychiatr. Serv. 2003, 54:508-516.
22. United States Congress.Congressional Budget Office Prices for brand-name drugs under selected federal programs. CBO Paper 2005.
23. Valenstein M., Copeland L.A., Blow F.C., McCarthy J.F., Zeber J.E., Gillon L., Bingham C.R., Stavenger T. Pharmacy data identify poorly adherent patients with schizophrenia at increased risk for admission. Med. Care 2002, 40:630-639.
24. Weiden P.J., Olfson M. Cost of relapse in schizophrenia. Schizophr. Bull. 1995, 21:419-429.
25. Woods S.W., Ziedonis D.M., Sernyak M.J., Diaz E., Rosenheck R.A. Characteristics of participants and nonparticipants in medication trials for treatment of schizophrenia. Psychiatr. Serv. 2000, 51:79-84.
26. Yang Y.K., Tarn Y.H., Wang T.Y., Liu C.Y., Laio Y.C., Chou Y.H., Lee S.M., Chen C.C. Pharmacoeconomic evaluation of schizophrenia in Taiwan: model comparison of long-acting risperidone versus olanzapine versus depot haloperidol based on estimated costs. Psychiatry Clin. Neurosci. 2005, 59:385-394.
27. Zhu B., Ascher-Svanum H., Faries D.E., Peng X., Salkever D., Slade E.P. Costs of treating patients with schizophrenia who have illness-related crisis events. BMC Psychiatry 2008, 8:72.